Neuland Laboratories share price today

Neuland Laboratories Ltd's share price was ₹19,576.00 at the close on 4 November 2026. It has been rising for 25 weeks. That is 5.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹11,995 and ₹23,536, and at that close it sat 66% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Neuland Laboratories Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 2 weeks running.

Over the last 11 years the share price moved +3,070% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: operating margin up 23 points on a year earlier and revenue up on a year earlier for 4 quarters in a row.

1. Operating margin up 23 points on a year earlier

   35% in the June 2026 quarter, from 12%.

   Why: Margins rose because the company sold a different mix of products, with more higher-margin business.

   Next results: check if the product mix keeps margins up, since exchange-rate help may change.

   From the earnings call on 5 Aug 2026.

2. Revenue up on a year earlier for 4 quarters in a row

   In the June 2026 quarter revenue was ₹642 crore, +119.1% on a year earlier.

   Why: Revenue rose because the custom manufacturing business supplied most sales, led by its top products.

   Next results: check whether new projects turn into orders and whether customers keep ordering steadily.

   From the earnings call on 5 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Neuland Laboratories reported revenue of ₹642 crore, up 119.1% from ₹293 crore a year earlier, and a profit of ₹148 crore, up 957.1% from ₹14.0 crore.

Neuland Laboratories results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Neuland Laboratories' management discussed these results on a call held on 5 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Neuland Laboratories closed at ₹19,576.00 on 4 November 2026, up 9.7% from ₹17,837.00 a year earlier (7 November 2025) and up 1,059.3% over five years. Its highest weekly close since March 2016 was ₹23,536.20 on 11 September 2026.

Neuland Laboratories share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

564 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Neuland Laboratories closed at ₹19,576.00, down 0.6% on the week and down 8.9% on the month. 5 Aug 2026: Neuland Laboratories held its results call for April to June 2026. Management guided: Long-term approximately 20% growth aspiration referenced for FY27 and FY28, without adopting a specific annual guide.

Earlier

• 24 Jul 2026: ex-date for a dividend of ₹34 a share.
• Results for April to June 2026: Revenue up 119.1% and profit up 957.1% on a year earlier.

Neuland Laboratories paid ₹34 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.17% at the ₹19,576.00 close on 4 November 2026. The last was a dividend of ₹34 a share, ex-date 24 July 2026.

Neuland Laboratories dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Neuland Laboratories Ltd paid out 12% of its profit as dividends in FY26, and it paid a dividend in 10 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 5 August 2026, Neuland Laboratories' management guided: Long-term approximately 20% growth aspiration referenced for FY27 and FY28, without adopting a specific annual guide.

“Therefore, you may see higher EBITDA, but in terms of our plans and our long-term expectations, 25% plus is what we would be targeting, and anything above that is a bonus.”Saharsh Davuluri, CEO & MD, on the call for April to June 2026

What management guided

• FY27 development revenue expected to increase; larger commercial contribution from additional molecules expected from FY28.
• CMS commercialization of one additional molecule expected this year and one or two next year.
• Peptide facility to be commissioned next month with manufacturing qualification; Module 1 expected fully occupied during the year and Module 2 activated if projects progress.
• Forward capital spending expected much higher and qualitatively different.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 5 August 2026.

When Neuland Laboratories reports July to September 2026, these are the 3 checks that show whether the story is still on course. First: Peptide facility commissioning and qualification - check initial-module loading and staged expansion progress in the next quarter.

Neuland Laboratories is on 3 of our India lists: Momentum stocks, Small & mid cap stocks and Pharma stocks.

Neuland Laboratories Ltd earned ₹148 Cr of net profit in the Jun 2026 quarter, +957.1% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹364 Cr. Over 10 years profit has grown 29.7% a year on average. That is 23.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹14.0 Cr.

For the full year, FY26 profit was ₹364 Cr (+40.0% on the year before).

Why profit moved: revenue changed +119.1% on a year earlier and the margin moved +23.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +438.0% and revenue +82.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Neuland Laboratories Ltd reported ₹642 Cr of revenue in the Jun 2026 quarter, +119.1% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 10 years it has grown 14.8% a year on average. The last full year, FY26, came in at ₹2,023 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,372 Cr.

FY26 revenue was ₹2,023 Cr, +37.0% on the year before.

Recent pace: the last four quarters grew +82.9% on average, against 14.8% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +78.3%, against +20.4% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +181.9%, against +21.9% a year (accelerating).

Neuland Laboratories Ltd's operating margin was 35.0% in the Jun 2026 quarter, 23.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 9.0% and 30.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +23.0 percentage points on the year while gross margin changed +4.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 100% of Neuland Laboratories Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹347 Cr of operating cash against ₹364 Cr of profit.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

After ₹477 Cr of spending on assets, free cash was −₹130 Cr: it spent more than its operations brought in.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 100% of profit came in as cash: the cash cycle got 50 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 3.7× depreciation over three years. The next section checks what that spending is building.

Neuland Laboratories Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 214 days in FY26, up from 164 days in FY21. It spent ₹807 Cr on assets over the last 3 years. Customers take 98 days to pay, and stock sits for 245 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,023 Cr, each day of that cycle ties up about ₹5.5 Cr, so roughly ₹1,186 Cr is tied up in the business at any time.

FY26: customers took 98 days to pay and stock sat for 245 days, about 8.1 months of sales sitting as stock, for a full cycle of 214 days, longer than FY21's 164.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 245 days. Customers pay about 98 days after that. Suppliers are paid at 129 days. Together that makes the 214-day cycle.

Spending on assets: ₹807 Cr over the last 3 years, against ₹218 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹211 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Neuland Laboratories Ltd's P/E is 50.5×, in the middle of its own history: higher than 68% of past readings. Its usual P/E (the middle reading) is 36.0×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.